# A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06730347/  
OnCo record `nct06730347` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Lorigerlimab in ovarian cancer and endometrial cancer, run by MacroGenics, now recruiting.

## Summary

A Study of Lorigerlimab in Participants With Advanced Solid Tumors is a phase 2 interventional study registered as NCT06730347 by MacroGenics, with 80 participants planned, started 2025-05-01 and due to reach its primary completion in 2027-07. Interventions recorded: Lorigerlimab. Conditions listed: Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06730347
- Phase: 2
- Setting: A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors
- Sponsor: MacroGenics
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT06730347: https://clinicaltrials.gov/study/NCT06730347

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Lorigerlimab](https://onco.cc/drugs/lorigerlimab/)
- companies: [MacroGenics](https://onco.cc/companies/macrogenics/)

---
JSON: https://onco.cc/api/v1/entities/nct06730347.json